Suppr超能文献

[通过药物重新定位开发神经疾病的新型治疗方法]

[Development of a Novel Treatment for Neurological Disorders by Drug Repositioning].

作者信息

Saito Satoshi, Ihara Masafumi

机构信息

Department of Neurology, National Cerebral and Cardiovascular Center.

出版信息

Brain Nerve. 2019 Sep;71(9):936-942. doi: 10.11477/mf.1416201385.

Abstract

The aim of drug repositioning is to identify and develop new uses for existing drugs. Many drugs for neurological disorders have been established by drug repositioning. Conventional drug repositioning approaches are based on chance findings or close clinical observations. Nowadays, computational drug repositioning can complement these approaches. Drug repositioning has many advantages. For example, unexpected adverse events occur less frequently in clinical trials using repositioned drugs than in trials with new drugs because safety information for repositioned drugs has often already accumulated before the start of a clinical trial. Another advantage is that drug repositioning can shorten the time needed for drug development and thereby reduce costs related to drug innovation. If results of pharmacological and toxic tests are available, pre-clinical studies may also be omitted. Drug repositioning is especially promising in the development of treatments for neurodegenerative disorders because the development of new drugs for chronic disorders often takes more than 20 years and has a high financial burden. Strategic patenting is important to cooperate with pharmaceutical companies and to accomplish drug repositioning.

摘要

药物重新定位的目的是识别并开发现有药物的新用途。许多用于治疗神经系统疾病的药物都是通过药物重新定位确定的。传统的药物重新定位方法基于偶然发现或密切的临床观察。如今,计算药物重新定位可以补充这些方法。药物重新定位有许多优点。例如,在使用重新定位药物的临床试验中,意外不良事件的发生频率低于使用新药的试验,因为重新定位药物的安全信息通常在临床试验开始前就已经积累。另一个优点是,药物重新定位可以缩短药物开发所需的时间,从而降低与药物创新相关的成本。如果有药理学和毒理学测试结果,也可以省略临床前研究。药物重新定位在神经退行性疾病治疗的开发中特别有前景,因为针对慢性疾病的新药开发通常需要20多年,且经济负担沉重。战略专利对于与制药公司合作以及实现药物重新定位很重要。

相似文献

1
[Development of a Novel Treatment for Neurological Disorders by Drug Repositioning].
Brain Nerve. 2019 Sep;71(9):936-942. doi: 10.11477/mf.1416201385.
2
Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases.
Curr Med Chem. 2018 Feb 12;25(4):525-539. doi: 10.2174/0929867324666170518094404.
3
Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
Curr Top Med Chem. 2016;16(19):2189-200. doi: 10.2174/1568026616666160216152138.
4
Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases.
Drug Discov Today. 2017 May;22(5):805-813. doi: 10.1016/j.drudis.2017.03.009. Epub 2017 Mar 29.
5
Drug repositioning: re-investigating existing drugs for new therapeutic indications.
J Postgrad Med. 2011 Apr-Jun;57(2):153-60. doi: 10.4103/0022-3859.81870.
6
Challenges and opportunities of drug repositioning.
Trends Pharmacol Sci. 2013 May;34(5):267-72. doi: 10.1016/j.tips.2013.03.004. Epub 2013 Apr 12.
7
A physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug repositioning.
BMC Syst Biol. 2016 Dec 5;10(Suppl 5):128. doi: 10.1186/s12918-016-0371-3.
8
Novel insight into drug repositioning: Methylthiouracil as a case in point.
Pharmacol Res. 2015 Sep;99:185-93. doi: 10.1016/j.phrs.2015.06.008. Epub 2015 Jun 25.
9
Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.
J Gynecol Oncol. 2019 Jan;30(1):e10. doi: 10.3802/jgo.2019.30.e10. Epub 2018 Oct 10.
10
Analysis of Drug Repositioning and Prediction Techniques: A Concise Review.
Curr Top Med Chem. 2022;22(23):1897-1906. doi: 10.2174/1568026622666220317164016.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验